Skip to main content

Table 1 :

From: Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy

 

No of diagnoses

Incidence per 1000 PY

Crude RR 95%CI

Adjusted RR Model 1* 95%CI

Adjusted Model 2** 95%CI

no cART and year<1996

43

0.58

1.35 [0.84;2.18]

1.14 [0.7;1.85]

0.68 [0.4;1.17]

no cART and year>=1996

28

0.79

1

1

1

[0;1]

6

2.01

3.48 [1.48;8.17]

3.09 [1.31;7.28]

1.75 [0.73;4.19]

[1;2]

2

0.68

1.19 [0.29;4.89]

1.05 [0.25;4.33]

0.30 [0.04;2.23]

[2;3]

7

2.35

4.11 [1.85;9.13]

3.62 [1.62;8.08]

2.17 [0.96;4.92]

[3;6]

8

0.94

1.63 [0.76;3.46]

1.43 [0.67;3.05]

0.90 [0.41;1.94]

≥6

93

0.58

1.00 [0.69;1.43]

0.83 [0.57;1.2]

0.75 [0.51;1.10]

  1. *adjusted for age, sex and exposure group, migration for sub-Saharan Africa, AIDS stage. **adjusted for variables in model 1 and CD4 cell count.